Market Research Logo

COPD Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies

COPD Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies

Summary


Chronic obstructive pulmonary disease (COPD) is a term that refers to a large group of lung diseases characterized by obstruction of air flow that interferes with normal breathing. COPD occurs most often in older people, but can also affect people in their middle ages. It is a major cause of chronic morbidity and mortality globally. Many people suffer from this disease for years, and die from it or its complications, and it constitutes a substantial economic and social burden.

Globally, the COPD burden is projected to increase in the coming decades because of continued exposure to COPD risk factors, and the increasing number of smokers. Increased smoking will result in a greater number of people living with the condition, thereby acting as a driver for revenue growth. The share of mortality attributed to COPD is expected to increase in the coming decades, when compared with other chronic diseases such as heart disease and stroke.

The marketed products landscape comprises a wide range of treatment options, including bronchodilator combinations, bronchodilator and ICS combinations, bronchodilator monotherapies and PDE-4 inhibitors. However, the market is undergoing a gradual transition, away from bronchodilator and ICS therapies and towards targeted and triple combination drug treatments. The market is set to be driven by recently launched products, and the approval of novel drugs that will supplement current market leaders and offer greater therapeutic options.

Scope

The COPD Asia-Pacific market will be valued at $7.3 billion in 2022, growing from $3.7 billion in 2015 at a CAGR of 10.2%.

  • Bronchodilators and ICS dominate the COPD market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the COPD market?
  • Do branded therapies show continuous growth, and are they facing any competition from generics?
  • How will branded therapies be affected by upcoming pipeline therapies?
The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies.
  • Which molecular targets appear most frequently in the pipeline?
  • Will the pipeline address unmet needs related to limited targeted therapies for COPD patients?
  • What first-in-class triple combinations are due to enter the COPD market within the forecast period, and how will they compete with the currently marketed products?
Market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the emergence of novel therapies.
  • How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
Various drivers and barriers will influence the market over the forecast period.
  • What barriers limit the uptake of premium-priced therapeutics in the assessed countries?
  • What factors are most likely to drive the market in these countries?
Reasons to buy

This report will allow you to -
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the COPD market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
  • Analyze the COPD pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict COPD market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as analysis of the contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.4.1 Pathophysiology
2.5 Diagnosis
2.6 Disease Stages
2.7 Prognosis
2.8 Treatment Options
2.8.1 Treatment Algorithm
3 Marketed Products
3.1 Overview
3.2 Bronchodilator Combination Therapy
3.2.1 Brimica/Duaklir Genuair (aclidinium/formoterol) - AstraZeneca
3.2.2 Spiolto/Stiolto Respimat (tiotropium/olodaterol) - Boehringer Ingelheim
3.2.3 Ultibro (glycopyrronium/indacaterol) - Novartis
3.2.4 Anoro Ellipta (umeclidinium/vilanterol) - GlaxoSmithKline/Theravance
3.2.5 Combivent (ipratropium/albuterol) - Boehringer Ingelheim
3.3 Bronchodilator and Inhaled Corticosteroid Combination Therapy
3.3.1 Symbicort (budesonide/formoterol) - AstraZeneca
3.3.2 Seretide/Advair (salmeterol/fluticasone) - GlaxoSmithKline
3.3.3 Relvar/Breo (fluticasone and vilanterol) - GlaxoSmithKline/Theravance
3.4 Bronchodilator Monotherapy
3.4.1 Spiriva (Tiotropium) - Boehringer Ingelheim
3.4.2 Foradil (formoterol) - Novartis
3.4.3 Onbrez/Arbeela/Arcapta (indacaterol) - Novartis
3.4.4 Seebri /Tovanor (glycopyrronium) - Novartis
3.4.5 Striverdi Respimat (Olodaterol) - Boehringer Ingelheim
3.5 Alternative therapy
3.5.1 Daxas (roflumilast) - Nycomeds
3.6 Marketed Products Heat Map
4 Pipeline Analysis
4.1 Overview
4.2 Pipeline Distribution by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline Distribution by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 Mepolizumab - GlaxoSmithKline
4.4.2 Benralizumab - AstraZeneca and MedImmune
4.4.3 PT003 - AstraZeneca/Pearl Therapeutics
4.4.4 PT010 - AstraZeneca/Pearl Therapeutics
4.4.5 Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate -GlaxoSmithKline
4.5 Heatmap for Pipeline Products
4.6 Product Competitiveness Framework
5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Duration
5.2.1 Clinical Trial Duration by Molecule Type
5.2.2 Clinical Trial Duration by Molecular Target
5.3 Clinical Trial Size
5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Phase
5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Phase
5.4 Competitive Clinical Trials Metrics Analysis
6 Multi-scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size
7 Drivers and Barriers
7.1 Drivers
7.1.1 Active Pipeline
7.1.2 Promising Late-Stage Pipeline Products Can Change Treatment Paradigm
7.1.3 Increasing Awareness of COPD
7.1.4 Ageing Population
7.2 Barriers
7.2.1 Sales Erosion by Generics
7.2.2 Growing Competition
7.2.3 Low Diagnosis Rates
8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-development Deals
9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Phase I
9.1.4 Phase II
9.1.5 Phase III
9.1.6 Pre-registration
9.2 Market Forecasts to 2021
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heatmap for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis
9.6 Contact Us
9.7 Disclaimer
1.1 List of Tables
Table 1: COPD Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
Table 2: COPD Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
Table 3: COPD Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
Table 4: COPD Therapeutics Market, Global, All Pipeline Products, Phase II, 2016
Table 5: COPD Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
Table 6: COPD Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2016
Table 7: COPD Therapeutics Market, Asia-Pacific, Market Forecast, 2015-2022
Table 8: COPD Therapeutics Market, India, Market Forecast, 2015-2022
Table 9: COPD Therapeutics Market, China, Market Forecast, 2015-2022
Table 10: COPD Therapeutics Market, Australia, Market Forecast, 2015-2022
Table 11: COPD Therapeutics Market, South Korea, Market Forecast, 2015-2022
Table 12: COPD Therapeutics Market, Japan, Market Forecast, 2015-2022
1.2 List of Figures
Figure 1: COPD Therapeutics Market, Treatment Algorithm of COPD
Figure 2: COPD Market, Global, Moderate-to-Severe COPD Marketed Products Heat Map, Efficacy, 2016
Figure 3: COPD Market, Global, Moderate-to-Severe COPD Marketed Products Heat Map, Safety, 2016
Figure 4: COPD Market, Global, Very Severe COPD Marketed Products Heat Map, Efficacy, 2016
Figure 5: COPD Market, Global, Very Severe COPD Marketed Products Heat Map, Safety, 2016
Figure 6: COPD Therapeutics Market, Global, Pipeline, 2016
Figure 7: COPD Therapeutics Market, Global, Pipeline by Molecular Target, 2016
Figure 8: Pipeline for COPD Therapeutics by Molecular Target and Stage of Development, Global, 2016
Figure 9: COPD Therapeutics Market, APAC, Mepolizumab Market ($m), 2019-2022
Figure 10: COPD Therapeutics Market, APAC, Benralizumab Market ($m), 2021-2022
Figure 11: COPD Therapeutics Market, APAC, PT003 Market ($m), 2018-2022
Figure 12: COPD Therapeutics Market, APAC, PT010 Market ($m), 2020-2022
Figure 13: COPD Therapeutics Market, APAC, FF/UMEC/VI Market ($m), 2020-2022
Figure 14: COPD Market, Global, Pipeline Heatmap, Efficacy, 2016
Figure 15: COPD Market, Global, Pipeline Heatmap, Safety, 2016
Figure 16: COPD Therapeutics Market, Global, Competitor Matrix for Efficacy of Marketed and Pipeline Products, 2016
Figure 17: COPD Therapeutics Market, Global, Competitor Matrix for Safety of Marketed and Pipeline Products, 2016
Figure 18: COPD Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016
Figure 19: COPD Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2016
Figure 20: COPD Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2016
Figure 21: COPD Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006-2016
Figure 22: COPD Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006-2016
Figure 23: COPD Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2016
Figure 24: COPD Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006-2016
Figure 25: COPD Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006-2016
Figure 26: COPD Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006-2016
Figure 27: COPD Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 28: COPD Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 29: COPD Therapeutics Market, Asia-Pacific, Treatment Patterns (million) and Market Size ($bn), 2015-2022
Figure 30: COPD Therapeutics Market, India, Treatment Patterns (million), 2015-2022
Figure 31: COPD Therapeutics Market, India, Annual Cost of Therapy ($), 2015-2022
Figure 32: COPD Therapeutics Market, India, Market Size ($m), 2015-2022
Figure 33: COPD Therapeutics Market, China, Treatment Patterns (million), 2015-2022
Figure 34: COPD Therapeutics Market, China, Annual Cost of Therapy ($), 2015-2022
Figure 35: COPD Therapeutics Market, China, Market Size ($bn), 2015-2022
Figure 36: COPD Therapeutics Market, Australia, Treatment Patterns (million), 2015-2022
Figure 37: COPD Therapeutics Market, Australia, Annual Cost of Therapy ($), 2015-2022
Figure 38: COPD Therapeutics Market, Australia, Market Size ($m), 2015-2022
Figure 39: COPD Therapeutics Market, South Korea, Treatment Patterns (million), 2015-2022
Figure 40: COPD Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022
Figure 41: COPD Therapeutics Market, South Korea, Market Size ($m), 2015-2022
Figure 42: COPD Therapeutics Market, Japan, Treatment Patterns (million), 2015-2022
Figure 43: COPD Therapeutics Market, Japan, Annual Cost of Therapy ($), 2015-2022
Figure 44: COPD Therapeutics Market, Japan, Market Size ($bn), 2015-2022
Figure 45: COPD Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016
Figure 46: COPD Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
Figure 47: COPD Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
Figure 48: COPD Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2016
Figure 49: COPD Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2016
Figure 50: COPD Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006-2016
Figure 51: COPD Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
Figure 52: COPD Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
Figure 53: COPD Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2006-2016
Figure 54: COPD Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report